Skip to content
10-K

Annual Report

IMMUNOVANT, INC. IMVT

0001764013-26-000064

← back to feed
Filed
May 20, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2026 · May 14, 2026 205.31M sh
Shares Diluted FY 2026 · Mar 31, 2026 182.42M sh
Shares Diluted FY 2026 · Mar 31, 2025 151.57M sh
Shares Diluted FY 2026 · Mar 31, 2024 138.1M sh
Capex FY 2026 · Mar 31, 2026 $8K
Capex FY 2026 · Mar 31, 2025 $759K
Capex FY 2026 · Mar 31, 2024 $360K
Operating Cash Flow FY 2026 · Mar 31, 2026 −$407.31M
Operating Cash Flow FY 2026 · Mar 31, 2025 −$375.87M
Operating Cash Flow FY 2026 · Mar 31, 2024 −$214.23M
Cash And Equivalents FY 2026 · Mar 31, 2026 $902.11M
Cash And Equivalents FY 2026 · Mar 31, 2025 $713.97M
Stockholders Equity FY 2026 · Mar 31, 2026 $852.59M
Stockholders Equity FY 2026 · Mar 31, 2025 $707.45M
Stockholders Equity FY 2026 · Mar 31, 2024 $617.76M
Stockholders Equity FY 2026 · Mar 31, 2023 $362.49M
Current Liabilities FY 2026 · Mar 31, 2026 $104.42M
Current Liabilities FY 2026 · Mar 31, 2025 $68.78M
Total Liabilities FY 2026 · Mar 31, 2026 $104.42M
Total Liabilities FY 2026 · Mar 31, 2025 $68.78M
Current Assets FY 2026 · Mar 31, 2026 $948.82M
Current Assets FY 2026 · Mar 31, 2025 $767.66M
Total Assets FY 2026 · Mar 31, 2026 $957.01M
Total Assets FY 2026 · Mar 31, 2025 $776.22M
Eps Diluted FY 2026 · Mar 31, 2026 −$2.77
Eps Diluted FY 2026 · Mar 31, 2025 −$2.73
Eps Diluted FY 2026 · Mar 31, 2024 −$1.88
Eps Basic FY 2026 · Mar 31, 2026 −$2.77
Eps Basic FY 2026 · Mar 31, 2025 −$2.73
Eps Basic FY 2026 · Mar 31, 2024 −$1.88
Sga Expense FY 2026 · Mar 31, 2026 $76.24M
Sga Expense FY 2026 · Mar 31, 2025 $77.24M
Sga Expense FY 2026 · Mar 31, 2024 $57.28M
Net Income FY 2026 · Mar 31, 2026 −$505.61M
Net Income FY 2026 · Mar 31, 2025 −$413.84M
Net Income FY 2026 · Mar 31, 2024 −$259.34M